nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—TEK—sarcoma	0.195	0.366	CbGaD
Nilotinib—PDGFRB—sarcoma	0.125	0.236	CbGaD
Nilotinib—PDGFRA—sarcoma	0.122	0.23	CbGaD
Nilotinib—KIT—sarcoma	0.0897	0.169	CbGaD
Nilotinib—CYP2B6—Thiotepa—sarcoma	0.0292	0.165	CbGbCtD
Nilotinib—UGT1A1—Etoposide—sarcoma	0.0205	0.116	CbGbCtD
Nilotinib—ABCG2—Dactinomycin—sarcoma	0.02	0.113	CbGbCtD
Nilotinib—ABCG2—Mitoxantrone—sarcoma	0.0179	0.101	CbGbCtD
Nilotinib—ABCG2—Vincristine—sarcoma	0.0123	0.0693	CbGbCtD
Nilotinib—ABCG2—Etoposide—sarcoma	0.0113	0.0635	CbGbCtD
Nilotinib—CYP3A4—Thiotepa—sarcoma	0.00898	0.0506	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—sarcoma	0.00768	0.0433	CbGbCtD
Nilotinib—ABCB1—Dactinomycin—sarcoma	0.0072	0.0406	CbGbCtD
Nilotinib—ABCB1—Mitoxantrone—sarcoma	0.00644	0.0363	CbGbCtD
Nilotinib—CYP2C8—Etoposide—sarcoma	0.006	0.0338	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—sarcoma	0.0054	0.0305	CbGbCtD
Nilotinib—ABCB1—Vincristine—sarcoma	0.00443	0.025	CbGbCtD
Nilotinib—ABCB1—Etoposide—sarcoma	0.00406	0.0229	CbGbCtD
Nilotinib—CYP3A4—Mitoxantrone—sarcoma	0.00386	0.0218	CbGbCtD
Nilotinib—ABCB1—Doxorubicin—sarcoma	0.00277	0.0156	CbGbCtD
Nilotinib—CYP3A4—Vincristine—sarcoma	0.00266	0.015	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—sarcoma	0.00261	0.0147	CbGbCtD
Nilotinib—CYP3A4—Etoposide—sarcoma	0.00243	0.0137	CbGbCtD
Nilotinib—CYP3A4—Doxorubicin—sarcoma	0.00166	0.00936	CbGbCtD
Nilotinib—Ponatinib—TEK—sarcoma	0.00126	0.24	CrCbGaD
Nilotinib—Ponatinib—PDGFRA—sarcoma	0.000792	0.151	CrCbGaD
Nilotinib—Ponatinib—SRC—sarcoma	0.000655	0.125	CrCbGaD
Nilotinib—Ponatinib—KDR—sarcoma	0.000616	0.117	CrCbGaD
Nilotinib—Ponatinib—KIT—sarcoma	0.000581	0.111	CrCbGaD
Nilotinib—Imatinib—PDGFRB—sarcoma	0.0005	0.0953	CrCbGaD
Nilotinib—Imatinib—PDGFRA—sarcoma	0.000487	0.0928	CrCbGaD
Nilotinib—Imatinib—KIT—sarcoma	0.000358	0.0681	CrCbGaD
Nilotinib—ABL1—Daunorubicin—Epirubicin—sarcoma	0.000291	0.173	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Epirubicin—sarcoma	0.000291	0.173	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—sarcoma	0.000291	0.173	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Doxorubicin—sarcoma	0.000269	0.16	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—sarcoma	0.000269	0.16	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—sarcoma	0.000269	0.16	CbGdCrCtD
Nilotinib—FGR—hematopoietic system—sarcoma	0.000269	0.00378	CbGeAlD
Nilotinib—BRAF—uterus—sarcoma	0.000267	0.00376	CbGeAlD
Nilotinib—EPHB3—uterus—sarcoma	0.000265	0.00373	CbGeAlD
Nilotinib—EPHA2—seminal vesicle—sarcoma	0.000264	0.00372	CbGeAlD
Nilotinib—MAPK14—connective tissue—sarcoma	0.00026	0.00366	CbGeAlD
Nilotinib—MAPK11—testis—sarcoma	0.00026	0.00366	CbGeAlD
Nilotinib—CDC42BPB—testis—sarcoma	0.000258	0.00363	CbGeAlD
Nilotinib—EPHB4—hematopoietic system—sarcoma	0.000256	0.0036	CbGeAlD
Nilotinib—MAP4K1—tendon—sarcoma	0.000256	0.0036	CbGeAlD
Nilotinib—ABL1—mammary gland—sarcoma	0.000254	0.00357	CbGeAlD
Nilotinib—EPHA2—hematopoietic system—sarcoma	0.000251	0.00353	CbGeAlD
Nilotinib—PDGFRA—embryo—sarcoma	0.000249	0.0035	CbGeAlD
Nilotinib—MAP4K1—bone marrow—sarcoma	0.000248	0.00349	CbGeAlD
Nilotinib—EPHB4—connective tissue—sarcoma	0.000247	0.00347	CbGeAlD
Nilotinib—EPHB6—seminal vesicle—sarcoma	0.000246	0.00347	CbGeAlD
Nilotinib—TEK—hematopoietic system—sarcoma	0.000245	0.00345	CbGeAlD
Nilotinib—EPHA3—testis—sarcoma	0.000244	0.00344	CbGeAlD
Nilotinib—CDC42BPB—liver—sarcoma	0.000244	0.00343	CbGeAlD
Nilotinib—HCK—uterus—sarcoma	0.000243	0.00343	CbGeAlD
Nilotinib—MAPK14—smooth muscle tissue—sarcoma	0.000238	0.00335	CbGeAlD
Nilotinib—TEK—connective tissue—sarcoma	0.000236	0.00332	CbGeAlD
Nilotinib—MAPK14—skin of body—sarcoma	0.000235	0.0033	CbGeAlD
Nilotinib—BRAF—tendon—sarcoma	0.000234	0.00329	CbGeAlD
Nilotinib—MAP2K5—myometrium—sarcoma	0.000233	0.00328	CbGeAlD
Nilotinib—MAPK8—testis—sarcoma	0.000233	0.00328	CbGeAlD
Nilotinib—EPHA6—testis—sarcoma	0.000233	0.00328	CbGeAlD
Nilotinib—CSF1R—myometrium—sarcoma	0.000228	0.0032	CbGeAlD
Nilotinib—HCK—lymphoid tissue—sarcoma	0.000227	0.00319	CbGeAlD
Nilotinib—BRAF—bone marrow—sarcoma	0.000227	0.00319	CbGeAlD
Nilotinib—EPHB4—smooth muscle tissue—sarcoma	0.000226	0.00317	CbGeAlD
Nilotinib—EPHA4—cardiac atrium—sarcoma	0.000222	0.00313	CbGeAlD
Nilotinib—PDGFRA—hematopoietic system—sarcoma	0.000222	0.00312	CbGeAlD
Nilotinib—EPHA4—uterus—sarcoma	0.000221	0.00311	CbGeAlD
Nilotinib—MAPK8—liver—sarcoma	0.00022	0.0031	CbGeAlD
Nilotinib—CA3—cardiac atrium—sarcoma	0.00022	0.00309	CbGeAlD
Nilotinib—CSF1R—embryo—sarcoma	0.000219	0.00308	CbGeAlD
Nilotinib—CA3—uterus—sarcoma	0.000219	0.00308	CbGeAlD
Nilotinib—TEK—smooth muscle tissue—sarcoma	0.000216	0.00304	CbGeAlD
Nilotinib—PDGFRA—connective tissue—sarcoma	0.000214	0.00301	CbGeAlD
Nilotinib—BLK—lymph node—sarcoma	0.000214	0.00301	CbGeAlD
Nilotinib—HCK—tendon—sarcoma	0.000213	0.003	CbGeAlD
Nilotinib—ABL2—tendon—sarcoma	0.000212	0.00298	CbGeAlD
Nilotinib—MAP4K1—testis—sarcoma	0.000212	0.00298	CbGeAlD
Nilotinib—UGT1A1—hematopoietic system—sarcoma	0.000212	0.00298	CbGeAlD
Nilotinib—MAP2K5—seminal vesicle—sarcoma	0.000211	0.00296	CbGeAlD
Nilotinib—KIT—myometrium—sarcoma	0.000207	0.00291	CbGeAlD
Nilotinib—HCK—bone marrow—sarcoma	0.000207	0.00291	CbGeAlD
Nilotinib—CSF1R—seminal vesicle—sarcoma	0.000206	0.00289	CbGeAlD
Nilotinib—MAPK14—uterus—sarcoma	0.000204	0.00287	CbGeAlD
Nilotinib—EPHB6—skin of body—sarcoma	0.000204	0.00286	CbGeAlD
Nilotinib—LYN—liver—sarcoma	0.000203	0.00286	CbGeAlD
Nilotinib—LCK—uterus—sarcoma	0.000203	0.00286	CbGeAlD
Nilotinib—TIE1—testis—sarcoma	0.000202	0.00284	CbGeAlD
Nilotinib—PDGFRB—myometrium—sarcoma	0.000202	0.00284	CbGeAlD
Nilotinib—CA14—cardiac atrium—sarcoma	0.0002	0.00281	CbGeAlD
Nilotinib—KIT—embryo—sarcoma	0.000199	0.0028	CbGeAlD
Nilotinib—CA12—connective tissue—sarcoma	0.000197	0.00278	CbGeAlD
Nilotinib—PDGFRA—smooth muscle tissue—sarcoma	0.000196	0.00275	CbGeAlD
Nilotinib—CSF1R—hematopoietic system—sarcoma	0.000195	0.00275	CbGeAlD
Nilotinib—EPHB4—cardiac atrium—sarcoma	0.000194	0.00274	CbGeAlD
Nilotinib—PDGFRB—embryo—sarcoma	0.000194	0.00273	CbGeAlD
Nilotinib—EPHA4—tendon—sarcoma	0.000194	0.00273	CbGeAlD
Nilotinib—BRAF—testis—sarcoma	0.000194	0.00273	CbGeAlD
Nilotinib—EPHB4—uterus—sarcoma	0.000193	0.00272	CbGeAlD
Nilotinib—EPHB3—testis—sarcoma	0.000192	0.0027	CbGeAlD
Nilotinib—CA3—tendon—sarcoma	0.000192	0.00269	CbGeAlD
Nilotinib—TIE1—liver—sarcoma	0.000191	0.00269	CbGeAlD
Nilotinib—EPHA2—cardiac atrium—sarcoma	0.000191	0.00268	CbGeAlD
Nilotinib—MAPK14—lymphoid tissue—sarcoma	0.00019	0.00268	CbGeAlD
Nilotinib—FGR—lymphoid tissue—sarcoma	0.000189	0.00266	CbGeAlD
Nilotinib—MAPK11—lymph node—sarcoma	0.000188	0.00265	CbGeAlD
Nilotinib—CSF1R—connective tissue—sarcoma	0.000188	0.00265	CbGeAlD
Nilotinib—CDC42BPB—lymph node—sarcoma	0.000187	0.00263	CbGeAlD
Nilotinib—KIT—seminal vesicle—sarcoma	0.000187	0.00263	CbGeAlD
Nilotinib—TEK—cardiac atrium—sarcoma	0.000186	0.00262	CbGeAlD
Nilotinib—CA3—bone marrow—sarcoma	0.000186	0.00261	CbGeAlD
Nilotinib—TEK—uterus—sarcoma	0.000185	0.0026	CbGeAlD
Nilotinib—CA9—tendon—sarcoma	0.000183	0.00258	CbGeAlD
Nilotinib—BRAF—liver—sarcoma	0.000183	0.00258	CbGeAlD
Nilotinib—PDGFRB—seminal vesicle—sarcoma	0.000182	0.00257	CbGeAlD
Nilotinib—ABL1—myometrium—sarcoma	0.00018	0.00253	CbGeAlD
Nilotinib—MAPK14—tendon—sarcoma	0.000179	0.00252	CbGeAlD
Nilotinib—FGR—tendon—sarcoma	0.000178	0.0025	CbGeAlD
Nilotinib—EPHB6—cardiac atrium—sarcoma	0.000178	0.0025	CbGeAlD
Nilotinib—KIT—hematopoietic system—sarcoma	0.000178	0.0025	CbGeAlD
Nilotinib—EPHA3—lymph node—sarcoma	0.000177	0.00249	CbGeAlD
Nilotinib—EPHA2—lymphoid tissue—sarcoma	0.000177	0.00249	CbGeAlD
Nilotinib—HCK—testis—sarcoma	0.000177	0.00249	CbGeAlD
Nilotinib—ABL2—testis—sarcoma	0.000176	0.00247	CbGeAlD
Nilotinib—CA14—tendon—sarcoma	0.000174	0.00245	CbGeAlD
Nilotinib—PDGFRB—hematopoietic system—sarcoma	0.000173	0.00244	CbGeAlD
Nilotinib—MAPK14—bone marrow—sarcoma	0.000173	0.00244	CbGeAlD
Nilotinib—ABL1—embryo—sarcoma	0.000173	0.00244	CbGeAlD
Nilotinib—TEK—lymphoid tissue—sarcoma	0.000173	0.00243	CbGeAlD
Nilotinib—FGR—bone marrow—sarcoma	0.000172	0.00243	CbGeAlD
Nilotinib—LCK—bone marrow—sarcoma	0.000172	0.00243	CbGeAlD
Nilotinib—CSF1R—smooth muscle tissue—sarcoma	0.000172	0.00242	CbGeAlD
Nilotinib—KIT—connective tissue—sarcoma	0.000171	0.0024	CbGeAlD
Nilotinib—CSF1R—skin of body—sarcoma	0.00017	0.00239	CbGeAlD
Nilotinib—EPHB4—tendon—sarcoma	0.000169	0.00238	CbGeAlD
Nilotinib—MAPK8—lymph node—sarcoma	0.000169	0.00238	CbGeAlD
Nilotinib—PDGFRA—uterus—sarcoma	0.000168	0.00236	CbGeAlD
Nilotinib—HCK—liver—sarcoma	0.000167	0.00235	CbGeAlD
Nilotinib—PDGFRB—connective tissue—sarcoma	0.000167	0.00235	CbGeAlD
Nilotinib—EPHA2—tendon—sarcoma	0.000166	0.00234	CbGeAlD
Nilotinib—ABL2—liver—sarcoma	0.000166	0.00233	CbGeAlD
Nilotinib—CYP2C8—mammary gland—sarcoma	0.000164	0.00231	CbGeAlD
Nilotinib—EPHB4—bone marrow—sarcoma	0.000164	0.00231	CbGeAlD
Nilotinib—ABL1—seminal vesicle—sarcoma	0.000163	0.00229	CbGeAlD
Nilotinib—CA1—hematopoietic system—sarcoma	0.000162	0.00228	CbGeAlD
Nilotinib—TEK—tendon—sarcoma	0.000162	0.00228	CbGeAlD
Nilotinib—EPHA4—testis—sarcoma	0.000161	0.00226	CbGeAlD
Nilotinib—CA3—testis—sarcoma	0.000159	0.00223	CbGeAlD
Nilotinib—KIT—smooth muscle tissue—sarcoma	0.000156	0.0022	CbGeAlD
Nilotinib—PDGFRA—lymphoid tissue—sarcoma	0.000156	0.0022	CbGeAlD
Nilotinib—EPHB6—tendon—sarcoma	0.000155	0.00218	CbGeAlD
Nilotinib—ABL1—hematopoietic system—sarcoma	0.000155	0.00217	CbGeAlD
Nilotinib—KIT—skin of body—sarcoma	0.000154	0.00217	CbGeAlD
Nilotinib—MAP4K1—lymph node—sarcoma	0.000154	0.00216	CbGeAlD
Nilotinib—PDGFRB—smooth muscle tissue—sarcoma	0.000153	0.00215	CbGeAlD
Nilotinib—MAP2K5—cardiac atrium—sarcoma	0.000152	0.00214	CbGeAlD
Nilotinib—CA9—testis—sarcoma	0.000152	0.00214	CbGeAlD
Nilotinib—PDGFRB—skin of body—sarcoma	0.000151	0.00212	CbGeAlD
Nilotinib—CA3—liver—sarcoma	0.00015	0.00211	CbGeAlD
Nilotinib—ABL1—connective tissue—sarcoma	0.000149	0.00209	CbGeAlD
Nilotinib—CSF1R—cardiac atrium—sarcoma	0.000148	0.00209	CbGeAlD
Nilotinib—MAPK14—testis—sarcoma	0.000148	0.00208	CbGeAlD
Nilotinib—CSF1R—uterus—sarcoma	0.000148	0.00208	CbGeAlD
Nilotinib—LCK—testis—sarcoma	0.000147	0.00207	CbGeAlD
Nilotinib—FGR—testis—sarcoma	0.000147	0.00207	CbGeAlD
Nilotinib—PDGFRA—tendon—sarcoma	0.000147	0.00207	CbGeAlD
Nilotinib—TIE1—lymph node—sarcoma	0.000146	0.00206	CbGeAlD
Nilotinib—CYP2C9—mammary gland—sarcoma	0.000146	0.00206	CbGeAlD
Nilotinib—BRAF—lymph node—sarcoma	0.00014	0.00198	CbGeAlD
Nilotinib—EPHB4—testis—sarcoma	0.00014	0.00197	CbGeAlD
Nilotinib—MAPK14—liver—sarcoma	0.00014	0.00197	CbGeAlD
Nilotinib—FGR—liver—sarcoma	0.000139	0.00196	CbGeAlD
Nilotinib—LCK—liver—sarcoma	0.000139	0.00196	CbGeAlD
Nilotinib—EPHB3—lymph node—sarcoma	0.000139	0.00196	CbGeAlD
Nilotinib—EPHA2—testis—sarcoma	0.000138	0.00194	CbGeAlD
Nilotinib—CSF1R—lymphoid tissue—sarcoma	0.000138	0.00194	CbGeAlD
Nilotinib—CA14—liver—sarcoma	0.000136	0.00192	CbGeAlD
Nilotinib—ABL1—smooth muscle tissue—sarcoma	0.000136	0.00191	CbGeAlD
Nilotinib—ABL1—skin of body—sarcoma	0.000134	0.00189	CbGeAlD
Nilotinib—TEK—testis—sarcoma	0.000134	0.00189	CbGeAlD
Nilotinib—KIT—uterus—sarcoma	0.000134	0.00189	CbGeAlD
Nilotinib—CA4—seminal vesicle—sarcoma	0.000134	0.00188	CbGeAlD
Nilotinib—EPHB4—liver—sarcoma	0.000133	0.00187	CbGeAlD
Nilotinib—MAP2K5—tendon—sarcoma	0.000133	0.00186	CbGeAlD
Nilotinib—PDGFRB—cardiac atrium—sarcoma	0.000132	0.00185	CbGeAlD
Nilotinib—PDGFRB—uterus—sarcoma	0.000131	0.00184	CbGeAlD
Nilotinib—EPHA2—liver—sarcoma	0.00013	0.00183	CbGeAlD
Nilotinib—CSF1R—tendon—sarcoma	0.000129	0.00182	CbGeAlD
Nilotinib—EPHB6—testis—sarcoma	0.000128	0.00181	CbGeAlD
Nilotinib—HCK—lymph node—sarcoma	0.000128	0.0018	CbGeAlD
Nilotinib—ABL2—lymph node—sarcoma	0.000127	0.00179	CbGeAlD
Nilotinib—TEK—liver—sarcoma	0.000127	0.00179	CbGeAlD
Nilotinib—CSF1R—bone marrow—sarcoma	0.000125	0.00176	CbGeAlD
Nilotinib—KIT—lymphoid tissue—sarcoma	0.000125	0.00176	CbGeAlD
Nilotinib—PDGFRB—lymphoid tissue—sarcoma	0.000122	0.00172	CbGeAlD
Nilotinib—PDGFRA—testis—sarcoma	0.000122	0.00171	CbGeAlD
Nilotinib—CA2—embryo—sarcoma	0.000118	0.00166	CbGeAlD
Nilotinib—ABL1—cardiac atrium—sarcoma	0.000117	0.00165	CbGeAlD
Nilotinib—ABL1—uterus—sarcoma	0.000117	0.00164	CbGeAlD
Nilotinib—EPHA4—lymph node—sarcoma	0.000116	0.00164	CbGeAlD
Nilotinib—PDGFRA—liver—sarcoma	0.000115	0.00162	CbGeAlD
Nilotinib—CA3—lymph node—sarcoma	0.000115	0.00162	CbGeAlD
Nilotinib—PDGFRB—tendon—sarcoma	0.000115	0.00161	CbGeAlD
Nilotinib—CA1—lymphoid tissue—sarcoma	0.000114	0.00161	CbGeAlD
Nilotinib—KIT—bone marrow—sarcoma	0.000114	0.0016	CbGeAlD
Nilotinib—ABCG2—myometrium—sarcoma	0.000113	0.0016	CbGeAlD
Nilotinib—PDGFRB—bone marrow—sarcoma	0.000111	0.00156	CbGeAlD
Nilotinib—CA2—seminal vesicle—sarcoma	0.000111	0.00156	CbGeAlD
Nilotinib—MAP2K5—testis—sarcoma	0.00011	0.00154	CbGeAlD
Nilotinib—UGT1A1—liver—sarcoma	0.00011	0.00154	CbGeAlD
Nilotinib—ABL1—lymphoid tissue—sarcoma	0.000109	0.00153	CbGeAlD
Nilotinib—MAPK14—lymph node—sarcoma	0.000107	0.00151	CbGeAlD
Nilotinib—CSF1R—testis—sarcoma	0.000107	0.00151	CbGeAlD
Nilotinib—FGR—lymph node—sarcoma	0.000107	0.0015	CbGeAlD
Nilotinib—LCK—lymph node—sarcoma	0.000107	0.0015	CbGeAlD
Nilotinib—CA2—hematopoietic system—sarcoma	0.000105	0.00148	CbGeAlD
Nilotinib—CA1—bone marrow—sarcoma	0.000104	0.00146	CbGeAlD
Nilotinib—MAP2K5—liver—sarcoma	0.000104	0.00146	CbGeAlD
Nilotinib—ABCG2—seminal vesicle—sarcoma	0.000103	0.00144	CbGeAlD
Nilotinib—ABL1—tendon—sarcoma	0.000102	0.00144	CbGeAlD
Nilotinib—EPHB4—lymph node—sarcoma	0.000102	0.00143	CbGeAlD
Nilotinib—CA2—connective tissue—sarcoma	0.000101	0.00143	CbGeAlD
Nilotinib—CSF1R—liver—sarcoma	0.000101	0.00142	CbGeAlD
Nilotinib—CYP2C8—hematopoietic system—sarcoma	0.0001	0.00141	CbGeAlD
Nilotinib—EPHA2—lymph node—sarcoma	9.98e-05	0.0014	CbGeAlD
Nilotinib—ABL1—bone marrow—sarcoma	9.91e-05	0.00139	CbGeAlD
Nilotinib—TEK—lymph node—sarcoma	9.74e-05	0.00137	CbGeAlD
Nilotinib—KIT—testis—sarcoma	9.73e-05	0.00137	CbGeAlD
Nilotinib—CA4—cardiac atrium—sarcoma	9.64e-05	0.00136	CbGeAlD
Nilotinib—PDGFRB—testis—sarcoma	9.5e-05	0.00134	CbGeAlD
Nilotinib—EPHB6—lymph node—sarcoma	9.3e-05	0.00131	CbGeAlD
Nilotinib—CA2—smooth muscle tissue—sarcoma	9.27e-05	0.0013	CbGeAlD
Nilotinib—KIT—liver—sarcoma	9.2e-05	0.00129	CbGeAlD
Nilotinib—CA2—skin of body—sarcoma	9.15e-05	0.00129	CbGeAlD
Nilotinib—CYP2B6—hematopoietic system—sarcoma	8.99e-05	0.00126	CbGeAlD
Nilotinib—PDGFRB—liver—sarcoma	8.98e-05	0.00126	CbGeAlD
Nilotinib—CYP2C9—hematopoietic system—sarcoma	8.9e-05	0.00125	CbGeAlD
Nilotinib—PDGFRA—lymph node—sarcoma	8.82e-05	0.00124	CbGeAlD
Nilotinib—ABL1—testis—sarcoma	8.47e-05	0.00119	CbGeAlD
Nilotinib—CA1—liver—sarcoma	8.41e-05	0.00118	CbGeAlD
Nilotinib—CA4—tendon—sarcoma	8.4e-05	0.00118	CbGeAlD
Nilotinib—CA4—bone marrow—sarcoma	8.13e-05	0.00114	CbGeAlD
Nilotinib—ABL1—liver—sarcoma	8.01e-05	0.00113	CbGeAlD
Nilotinib—CA2—cardiac atrium—sarcoma	7.99e-05	0.00112	CbGeAlD
Nilotinib—MAP2K5—lymph node—sarcoma	7.96e-05	0.00112	CbGeAlD
Nilotinib—CYP2B6—skin of body—sarcoma	7.82e-05	0.0011	CbGeAlD
Nilotinib—CSF1R—lymph node—sarcoma	7.76e-05	0.00109	CbGeAlD
Nilotinib—CA2—lymphoid tissue—sarcoma	7.41e-05	0.00104	CbGeAlD
Nilotinib—ABCG2—uterus—sarcoma	7.36e-05	0.00104	CbGeAlD
Nilotinib—KIT—lymph node—sarcoma	7.05e-05	0.000992	CbGeAlD
Nilotinib—CA2—tendon—sarcoma	6.96e-05	0.00098	CbGeAlD
Nilotinib—CA4—testis—sarcoma	6.95e-05	0.000978	CbGeAlD
Nilotinib—PDGFRB—lymph node—sarcoma	6.89e-05	0.000969	CbGeAlD
Nilotinib—CYP3A4—hematopoietic system—sarcoma	6.79e-05	0.000955	CbGeAlD
Nilotinib—CA2—bone marrow—sarcoma	6.75e-05	0.000949	CbGeAlD
Nilotinib—CYP2D6—hematopoietic system—sarcoma	6.68e-05	0.00094	CbGeAlD
Nilotinib—CA1—lymph node—sarcoma	6.45e-05	0.000907	CbGeAlD
Nilotinib—CYP2B6—lymphoid tissue—sarcoma	6.33e-05	0.00089	CbGeAlD
Nilotinib—ABCG2—bone marrow—sarcoma	6.25e-05	0.000879	CbGeAlD
Nilotinib—ABL1—lymph node—sarcoma	6.14e-05	0.000863	CbGeAlD
Nilotinib—CA2—testis—sarcoma	5.77e-05	0.000811	CbGeAlD
Nilotinib—ABCB1—myometrium—sarcoma	5.6e-05	0.000787	CbGeAlD
Nilotinib—Weight decreased—Epirubicin—sarcoma	5.5e-05	0.00062	CcSEcCtD
Nilotinib—Dyspnoea—Etoposide—sarcoma	5.5e-05	0.00062	CcSEcCtD
Nilotinib—CYP2C8—testis—sarcoma	5.49e-05	0.000773	CbGeAlD
Nilotinib—Hyperglycaemia—Epirubicin—sarcoma	5.49e-05	0.000618	CcSEcCtD
Nilotinib—Angina pectoris—Doxorubicin—sarcoma	5.48e-05	0.000618	CcSEcCtD
Nilotinib—Hypersensitivity—Mitoxantrone—sarcoma	5.47e-05	0.000616	CcSEcCtD
Nilotinib—Asthenia—Vincristine—sarcoma	5.47e-05	0.000616	CcSEcCtD
Nilotinib—Vomiting—Thiotepa—sarcoma	5.46e-05	0.000616	CcSEcCtD
Nilotinib—Pneumonia—Epirubicin—sarcoma	5.46e-05	0.000615	CcSEcCtD
Nilotinib—CA2—liver—sarcoma	5.45e-05	0.000767	CbGeAlD
Nilotinib—Infestation—Epirubicin—sarcoma	5.42e-05	0.000611	CcSEcCtD
Nilotinib—Infestation NOS—Epirubicin—sarcoma	5.42e-05	0.000611	CcSEcCtD
Nilotinib—Vomiting—Dactinomycin—sarcoma	5.42e-05	0.000611	CcSEcCtD
Nilotinib—Rash—Thiotepa—sarcoma	5.42e-05	0.00061	CcSEcCtD
Nilotinib—Bronchitis—Doxorubicin—sarcoma	5.41e-05	0.00061	CcSEcCtD
Nilotinib—Dermatitis—Thiotepa—sarcoma	5.41e-05	0.00061	CcSEcCtD
Nilotinib—Headache—Thiotepa—sarcoma	5.38e-05	0.000606	CcSEcCtD
Nilotinib—ABCB1—embryo—sarcoma	5.38e-05	0.000757	CbGeAlD
Nilotinib—Rash—Dactinomycin—sarcoma	5.38e-05	0.000606	CcSEcCtD
Nilotinib—Decreased appetite—Etoposide—sarcoma	5.37e-05	0.000605	CcSEcCtD
Nilotinib—Pancytopenia—Doxorubicin—sarcoma	5.35e-05	0.000602	CcSEcCtD
Nilotinib—ABCG2—testis—sarcoma	5.34e-05	0.000751	CbGeAlD
Nilotinib—Renal failure—Epirubicin—sarcoma	5.33e-05	0.000601	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Etoposide—sarcoma	5.33e-05	0.0006	CcSEcCtD
Nilotinib—Asthenia—Mitoxantrone—sarcoma	5.32e-05	0.0006	CcSEcCtD
Nilotinib—Fatigue—Etoposide—sarcoma	5.32e-05	0.0006	CcSEcCtD
Nilotinib—Neuropathy peripheral—Epirubicin—sarcoma	5.32e-05	0.000599	CcSEcCtD
Nilotinib—Stomatitis—Epirubicin—sarcoma	5.29e-05	0.000596	CcSEcCtD
Nilotinib—Jaundice—Epirubicin—sarcoma	5.29e-05	0.000596	CcSEcCtD
Nilotinib—Pain—Etoposide—sarcoma	5.28e-05	0.000595	CcSEcCtD
Nilotinib—Constipation—Etoposide—sarcoma	5.28e-05	0.000595	CcSEcCtD
Nilotinib—Urinary tract infection—Epirubicin—sarcoma	5.27e-05	0.000594	CcSEcCtD
Nilotinib—Conjunctivitis—Epirubicin—sarcoma	5.27e-05	0.000594	CcSEcCtD
Nilotinib—Dysuria—Doxorubicin—sarcoma	5.26e-05	0.000593	CcSEcCtD
Nilotinib—Neutropenia—Doxorubicin—sarcoma	5.26e-05	0.000593	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Doxorubicin—sarcoma	5.23e-05	0.000589	CcSEcCtD
Nilotinib—Diarrhoea—Vincristine—sarcoma	5.21e-05	0.000587	CcSEcCtD
Nilotinib—Pollakiuria—Doxorubicin—sarcoma	5.2e-05	0.000586	CcSEcCtD
Nilotinib—CYP2C8—liver—sarcoma	5.19e-05	0.00073	CbGeAlD
Nilotinib—Haematuria—Epirubicin—sarcoma	5.17e-05	0.000583	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—sarcoma	5.14e-05	0.000579	CcSEcCtD
Nilotinib—Hepatobiliary disease—Epirubicin—sarcoma	5.13e-05	0.000578	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—sarcoma	5.12e-05	0.000577	CcSEcCtD
Nilotinib—Epistaxis—Epirubicin—sarcoma	5.12e-05	0.000576	CcSEcCtD
Nilotinib—Nausea—Thiotepa—sarcoma	5.1e-05	0.000575	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—sarcoma	5.09e-05	0.000574	CcSEcCtD
Nilotinib—Feeling abnormal—Etoposide—sarcoma	5.09e-05	0.000573	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—sarcoma	5.08e-05	0.000572	CcSEcCtD
Nilotinib—Diarrhoea—Mitoxantrone—sarcoma	5.08e-05	0.000572	CcSEcCtD
Nilotinib—Nausea—Dactinomycin—sarcoma	5.07e-05	0.000571	CcSEcCtD
Nilotinib—ABCB1—seminal vesicle—sarcoma	5.06e-05	0.000711	CbGeAlD
Nilotinib—Pneumonia—Doxorubicin—sarcoma	5.05e-05	0.000569	CcSEcCtD
Nilotinib—ABCG2—liver—sarcoma	5.05e-05	0.00071	CbGeAlD
Nilotinib—Gastrointestinal pain—Etoposide—sarcoma	5.05e-05	0.000569	CcSEcCtD
Nilotinib—CA4—lymph node—sarcoma	5.04e-05	0.000709	CbGeAlD
Nilotinib—Dizziness—Vincristine—sarcoma	5.04e-05	0.000568	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—sarcoma	5.02e-05	0.000566	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—sarcoma	5.02e-05	0.000566	CcSEcCtD
Nilotinib—Bradycardia—Epirubicin—sarcoma	4.96e-05	0.000559	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—sarcoma	4.93e-05	0.000556	CcSEcCtD
Nilotinib—CYP2B6—testis—sarcoma	4.93e-05	0.000693	CbGeAlD
Nilotinib—Neuropathy peripheral—Doxorubicin—sarcoma	4.92e-05	0.000554	CcSEcCtD
Nilotinib—Urticaria—Etoposide—sarcoma	4.9e-05	0.000552	CcSEcCtD
Nilotinib—Haemoglobin—Epirubicin—sarcoma	4.89e-05	0.000551	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—sarcoma	4.89e-05	0.000551	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—sarcoma	4.89e-05	0.000551	CcSEcCtD
Nilotinib—Rhinitis—Epirubicin—sarcoma	4.88e-05	0.00055	CcSEcCtD
Nilotinib—Body temperature increased—Etoposide—sarcoma	4.88e-05	0.00055	CcSEcCtD
Nilotinib—Abdominal pain—Etoposide—sarcoma	4.88e-05	0.00055	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—sarcoma	4.88e-05	0.00055	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—sarcoma	4.88e-05	0.00055	CcSEcCtD
Nilotinib—Hepatitis—Epirubicin—sarcoma	4.87e-05	0.000549	CcSEcCtD
Nilotinib—Haemorrhage—Epirubicin—sarcoma	4.87e-05	0.000549	CcSEcCtD
Nilotinib—Hypoaesthesia—Epirubicin—sarcoma	4.85e-05	0.000546	CcSEcCtD
Nilotinib—Vomiting—Vincristine—sarcoma	4.84e-05	0.000546	CcSEcCtD
Nilotinib—Pharyngitis—Epirubicin—sarcoma	4.83e-05	0.000545	CcSEcCtD
Nilotinib—Urinary tract disorder—Epirubicin—sarcoma	4.81e-05	0.000542	CcSEcCtD
Nilotinib—ABCB1—hematopoietic system—sarcoma	4.8e-05	0.000676	CbGeAlD
Nilotinib—Rash—Vincristine—sarcoma	4.8e-05	0.000541	CcSEcCtD
Nilotinib—Dermatitis—Vincristine—sarcoma	4.8e-05	0.000541	CcSEcCtD
Nilotinib—Oedema peripheral—Epirubicin—sarcoma	4.8e-05	0.000541	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—sarcoma	4.79e-05	0.000539	CcSEcCtD
Nilotinib—Connective tissue disorder—Epirubicin—sarcoma	4.79e-05	0.000539	CcSEcCtD
Nilotinib—Urethral disorder—Epirubicin—sarcoma	4.77e-05	0.000538	CcSEcCtD
Nilotinib—Headache—Vincristine—sarcoma	4.77e-05	0.000538	CcSEcCtD
Nilotinib—Hepatobiliary disease—Doxorubicin—sarcoma	4.75e-05	0.000535	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—sarcoma	4.73e-05	0.000533	CcSEcCtD
Nilotinib—Vomiting—Mitoxantrone—sarcoma	4.72e-05	0.000532	CcSEcCtD
Nilotinib—Visual impairment—Epirubicin—sarcoma	4.69e-05	0.000529	CcSEcCtD
Nilotinib—Rash—Mitoxantrone—sarcoma	4.68e-05	0.000527	CcSEcCtD
Nilotinib—Dermatitis—Mitoxantrone—sarcoma	4.67e-05	0.000527	CcSEcCtD
Nilotinib—CYP2B6—liver—sarcoma	4.66e-05	0.000655	CbGeAlD
Nilotinib—Headache—Mitoxantrone—sarcoma	4.65e-05	0.000524	CcSEcCtD
Nilotinib—CYP2C9—liver—sarcoma	4.61e-05	0.000649	CbGeAlD
Nilotinib—Erythema multiforme—Epirubicin—sarcoma	4.6e-05	0.000519	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—sarcoma	4.59e-05	0.000517	CcSEcCtD
Nilotinib—Eye disorder—Epirubicin—sarcoma	4.55e-05	0.000513	CcSEcCtD
Nilotinib—Hypersensitivity—Etoposide—sarcoma	4.55e-05	0.000512	CcSEcCtD
Nilotinib—Tinnitus—Epirubicin—sarcoma	4.54e-05	0.000512	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—sarcoma	4.53e-05	0.00051	CcSEcCtD
Nilotinib—Nausea—Vincristine—sarcoma	4.53e-05	0.00051	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—sarcoma	4.52e-05	0.000509	CcSEcCtD
Nilotinib—Flushing—Epirubicin—sarcoma	4.52e-05	0.000509	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—sarcoma	4.52e-05	0.000509	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—sarcoma	4.51e-05	0.000508	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—sarcoma	4.51e-05	0.000508	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—sarcoma	4.48e-05	0.000505	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—sarcoma	4.47e-05	0.000504	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—sarcoma	4.45e-05	0.000501	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—sarcoma	4.44e-05	0.0005	CcSEcCtD
Nilotinib—Asthenia—Etoposide—sarcoma	4.43e-05	0.000499	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—sarcoma	4.43e-05	0.000499	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—sarcoma	4.42e-05	0.000498	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—sarcoma	4.42e-05	0.000498	CcSEcCtD
Nilotinib—Nausea—Mitoxantrone—sarcoma	4.41e-05	0.000497	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—sarcoma	4.4e-05	0.000496	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—sarcoma	4.39e-05	0.000494	CcSEcCtD
Nilotinib—Chills—Epirubicin—sarcoma	4.37e-05	0.000492	CcSEcCtD
Nilotinib—Pruritus—Etoposide—sarcoma	4.37e-05	0.000492	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—sarcoma	4.35e-05	0.00049	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—sarcoma	4.34e-05	0.000489	CcSEcCtD
Nilotinib—Alopecia—Epirubicin—sarcoma	4.3e-05	0.000485	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—sarcoma	4.27e-05	0.000481	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—sarcoma	4.26e-05	0.00048	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—sarcoma	4.24e-05	0.000478	CcSEcCtD
Nilotinib—Erythema—Epirubicin—sarcoma	4.24e-05	0.000478	CcSEcCtD
Nilotinib—Diarrhoea—Etoposide—sarcoma	4.22e-05	0.000476	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—sarcoma	4.21e-05	0.000474	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—sarcoma	4.2e-05	0.000473	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—sarcoma	4.18e-05	0.000471	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—sarcoma	4.18e-05	0.000471	CcSEcCtD
Nilotinib—CA2—lymph node—sarcoma	4.18e-05	0.000588	CbGeAlD
Nilotinib—Flatulence—Epirubicin—sarcoma	4.18e-05	0.000471	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—sarcoma	4.15e-05	0.000468	CcSEcCtD
Nilotinib—Back pain—Epirubicin—sarcoma	4.1e-05	0.000462	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—sarcoma	4.09e-05	0.000461	CcSEcCtD
Nilotinib—Dizziness—Etoposide—sarcoma	4.08e-05	0.00046	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—sarcoma	4.08e-05	0.000459	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—sarcoma	4.07e-05	0.000459	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—sarcoma	4.06e-05	0.000458	CcSEcCtD
Nilotinib—Chills—Doxorubicin—sarcoma	4.04e-05	0.000456	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—sarcoma	4.03e-05	0.000454	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—sarcoma	4e-05	0.00045	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—sarcoma	3.98e-05	0.000449	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—sarcoma	3.95e-05	0.000445	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—sarcoma	3.93e-05	0.000443	CcSEcCtD
Nilotinib—Vomiting—Etoposide—sarcoma	3.92e-05	0.000442	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—sarcoma	3.92e-05	0.000442	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—sarcoma	3.92e-05	0.000442	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—sarcoma	3.92e-05	0.000441	CcSEcCtD
Nilotinib—Rash—Etoposide—sarcoma	3.89e-05	0.000438	CcSEcCtD
Nilotinib—Dermatitis—Etoposide—sarcoma	3.89e-05	0.000438	CcSEcCtD
Nilotinib—ABCG2—lymph node—sarcoma	3.87e-05	0.000545	CbGeAlD
Nilotinib—Headache—Etoposide—sarcoma	3.87e-05	0.000436	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—sarcoma	3.87e-05	0.000435	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—sarcoma	3.84e-05	0.000433	CcSEcCtD
Nilotinib—Malaise—Epirubicin—sarcoma	3.82e-05	0.000431	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—sarcoma	3.81e-05	0.000429	CcSEcCtD
Nilotinib—Syncope—Epirubicin—sarcoma	3.8e-05	0.000428	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—sarcoma	3.79e-05	0.000428	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—sarcoma	3.79e-05	0.000427	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—sarcoma	3.77e-05	0.000425	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—sarcoma	3.75e-05	0.000422	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—sarcoma	3.73e-05	0.00042	CcSEcCtD
Nilotinib—Cough—Epirubicin—sarcoma	3.7e-05	0.000417	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—sarcoma	3.7e-05	0.000417	CcSEcCtD
Nilotinib—Nausea—Etoposide—sarcoma	3.67e-05	0.000413	CcSEcCtD
Nilotinib—CYP2D6—testis—sarcoma	3.66e-05	0.000515	CbGeAlD
Nilotinib—Hypertension—Epirubicin—sarcoma	3.66e-05	0.000412	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—sarcoma	3.64e-05	0.00041	CcSEcCtD
Nilotinib—ABCB1—uterus—sarcoma	3.63e-05	0.000511	CbGeAlD
Nilotinib—Anaemia—Doxorubicin—sarcoma	3.63e-05	0.000408	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—sarcoma	3.61e-05	0.000407	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—sarcoma	3.61e-05	0.000407	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—sarcoma	3.61e-05	0.000407	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—sarcoma	3.6e-05	0.000405	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	3.58e-05	0.000404	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—sarcoma	3.57e-05	0.000402	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—sarcoma	3.54e-05	0.000399	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—sarcoma	3.53e-05	0.000398	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—sarcoma	3.52e-05	0.000397	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—sarcoma	3.52e-05	0.000396	CcSEcCtD
Nilotinib—CYP3A4—liver—sarcoma	3.52e-05	0.000495	CbGeAlD
Nilotinib—Leukopenia—Doxorubicin—sarcoma	3.51e-05	0.000396	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—sarcoma	3.49e-05	0.000393	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—sarcoma	3.47e-05	0.000391	CcSEcCtD
Nilotinib—CYP2D6—liver—sarcoma	3.46e-05	0.000487	CbGeAlD
Nilotinib—Oedema—Epirubicin—sarcoma	3.46e-05	0.00039	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—sarcoma	3.45e-05	0.000388	CcSEcCtD
Nilotinib—Infection—Epirubicin—sarcoma	3.44e-05	0.000387	CcSEcCtD
Nilotinib—Cough—Doxorubicin—sarcoma	3.42e-05	0.000386	CcSEcCtD
Nilotinib—Shock—Epirubicin—sarcoma	3.4e-05	0.000384	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—sarcoma	3.39e-05	0.000382	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—sarcoma	3.39e-05	0.000382	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—sarcoma	3.39e-05	0.000382	CcSEcCtD
Nilotinib—ABCB1—lymphoid tissue—sarcoma	3.38e-05	0.000476	CbGeAlD
Nilotinib—Tachycardia—Epirubicin—sarcoma	3.38e-05	0.00038	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—sarcoma	3.36e-05	0.000379	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—sarcoma	3.34e-05	0.000377	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—sarcoma	3.34e-05	0.000376	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—sarcoma	3.34e-05	0.000376	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—sarcoma	3.34e-05	0.000376	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—sarcoma	3.33e-05	0.000375	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	3.32e-05	0.000374	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—sarcoma	3.3e-05	0.000372	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—sarcoma	3.3e-05	0.000372	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—sarcoma	3.27e-05	0.000368	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—sarcoma	3.23e-05	0.000364	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—sarcoma	3.23e-05	0.000364	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—sarcoma	3.2e-05	0.000361	CcSEcCtD
Nilotinib—Infection—Doxorubicin—sarcoma	3.18e-05	0.000358	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—sarcoma	3.15e-05	0.000355	CcSEcCtD
Nilotinib—Shock—Doxorubicin—sarcoma	3.15e-05	0.000355	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—sarcoma	3.14e-05	0.000354	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—sarcoma	3.13e-05	0.000353	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—sarcoma	3.13e-05	0.000353	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—sarcoma	3.12e-05	0.000352	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—sarcoma	3.11e-05	0.00035	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—sarcoma	3.11e-05	0.00035	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—sarcoma	3.09e-05	0.000349	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—sarcoma	3.08e-05	0.000348	CcSEcCtD
Nilotinib—ABCB1—bone marrow—sarcoma	3.08e-05	0.000433	CbGeAlD
Nilotinib—Anorexia—Doxorubicin—sarcoma	3.05e-05	0.000344	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—sarcoma	3.05e-05	0.000343	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—sarcoma	3.01e-05	0.000339	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—sarcoma	2.99e-05	0.000337	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—sarcoma	2.99e-05	0.000337	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—sarcoma	2.98e-05	0.000336	CcSEcCtD
Nilotinib—Constipation—Epirubicin—sarcoma	2.96e-05	0.000333	CcSEcCtD
Nilotinib—Pain—Epirubicin—sarcoma	2.96e-05	0.000333	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—sarcoma	2.92e-05	0.000329	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—sarcoma	2.9e-05	0.000326	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—sarcoma	2.87e-05	0.000324	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—sarcoma	2.85e-05	0.000322	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—sarcoma	2.85e-05	0.000321	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—sarcoma	2.83e-05	0.000319	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—sarcoma	2.82e-05	0.000317	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—sarcoma	2.78e-05	0.000314	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—sarcoma	2.76e-05	0.000311	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—sarcoma	2.76e-05	0.000311	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—sarcoma	2.75e-05	0.00031	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—sarcoma	2.74e-05	0.000308	CcSEcCtD
Nilotinib—Pain—Doxorubicin—sarcoma	2.74e-05	0.000308	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—sarcoma	2.74e-05	0.000308	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—sarcoma	2.74e-05	0.000308	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—sarcoma	2.64e-05	0.000297	CcSEcCtD
Nilotinib—ABCB1—testis—sarcoma	2.63e-05	0.00037	CbGeAlD
Nilotinib—Gastrointestinal pain—Doxorubicin—sarcoma	2.62e-05	0.000295	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—sarcoma	2.55e-05	0.000287	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—sarcoma	2.54e-05	0.000287	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—sarcoma	2.53e-05	0.000285	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—sarcoma	2.53e-05	0.000285	CcSEcCtD
Nilotinib—ABCB1—liver—sarcoma	2.49e-05	0.00035	CbGeAlD
Nilotinib—Asthenia—Epirubicin—sarcoma	2.48e-05	0.00028	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—sarcoma	2.45e-05	0.000276	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—sarcoma	2.37e-05	0.000267	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—sarcoma	2.36e-05	0.000266	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—sarcoma	2.3e-05	0.000259	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—sarcoma	2.29e-05	0.000258	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—sarcoma	2.26e-05	0.000255	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—sarcoma	2.2e-05	0.000248	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—sarcoma	2.19e-05	0.000247	CcSEcCtD
Nilotinib—Rash—Epirubicin—sarcoma	2.18e-05	0.000246	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—sarcoma	2.18e-05	0.000246	CcSEcCtD
Nilotinib—Headache—Epirubicin—sarcoma	2.17e-05	0.000244	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—sarcoma	2.12e-05	0.000239	CcSEcCtD
Nilotinib—Nausea—Epirubicin—sarcoma	2.06e-05	0.000232	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—sarcoma	2.04e-05	0.000229	CcSEcCtD
Nilotinib—Rash—Doxorubicin—sarcoma	2.02e-05	0.000227	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—sarcoma	2.02e-05	0.000227	CcSEcCtD
Nilotinib—Headache—Doxorubicin—sarcoma	2.01e-05	0.000226	CcSEcCtD
Nilotinib—ABCB1—lymph node—sarcoma	1.91e-05	0.000269	CbGeAlD
Nilotinib—Nausea—Doxorubicin—sarcoma	1.9e-05	0.000214	CcSEcCtD
Nilotinib—MAPK8—Immune System—HRAS—sarcoma	2.26e-06	1.82e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—HRAS—sarcoma	2.26e-06	1.82e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CREB1—sarcoma	2.26e-06	1.82e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—HBA1—sarcoma	2.25e-06	1.82e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—sarcoma	2.25e-06	1.82e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—HRAS—sarcoma	2.25e-06	1.82e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—NRAS—sarcoma	2.25e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KDR—sarcoma	2.25e-06	1.81e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—KRAS—sarcoma	2.24e-06	1.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—sarcoma	2.24e-06	1.81e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HRAS—sarcoma	2.23e-06	1.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CTNNB1—sarcoma	2.23e-06	1.8e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—NRAS—sarcoma	2.22e-06	1.79e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—sarcoma	2.21e-06	1.79e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PLCG1—sarcoma	2.21e-06	1.78e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—sarcoma	2.21e-06	1.78e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HRAS—sarcoma	2.21e-06	1.78e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCND1—sarcoma	2.2e-06	1.78e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KDR—sarcoma	2.2e-06	1.77e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—JUN—sarcoma	2.2e-06	1.77e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—sarcoma	2.2e-06	1.77e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—JUN—sarcoma	2.19e-06	1.77e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CREB1—sarcoma	2.19e-06	1.76e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CTNNB1—sarcoma	2.18e-06	1.76e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—SRC—sarcoma	2.18e-06	1.76e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FOXO1—sarcoma	2.18e-06	1.76e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PDGFRB—sarcoma	2.18e-06	1.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CTNNB1—sarcoma	2.18e-06	1.75e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KRAS—sarcoma	2.15e-06	1.74e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—JUN—sarcoma	2.15e-06	1.73e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PDGFRA—sarcoma	2.14e-06	1.73e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ENO2—sarcoma	2.14e-06	1.72e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—JUN—sarcoma	2.14e-06	1.72e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CTNNB1—sarcoma	2.13e-06	1.72e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—SRC—sarcoma	2.13e-06	1.72e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—HBA1—sarcoma	2.12e-06	1.71e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MDM2—sarcoma	2.12e-06	1.71e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CTNNB1—sarcoma	2.12e-06	1.71e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ENO2—sarcoma	2.12e-06	1.71e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—HRAS—sarcoma	2.12e-06	1.71e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—KRAS—sarcoma	2.12e-06	1.71e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—HBA1—sarcoma	2.11e-06	1.7e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MDM2—sarcoma	2.1e-06	1.69e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NRAS—sarcoma	2.1e-06	1.69e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—MYC—sarcoma	2.1e-06	1.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—sarcoma	2.09e-06	1.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KDR—sarcoma	2.09e-06	1.68e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—SRC—sarcoma	2.08e-06	1.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KIT—sarcoma	2.07e-06	1.67e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—sarcoma	2.05e-06	1.65e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NRAS—sarcoma	2.05e-06	1.65e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—JUN—sarcoma	2.03e-06	1.64e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KIT—sarcoma	2.03e-06	1.63e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MDM2—sarcoma	2.02e-06	1.63e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—sarcoma	2.02e-06	1.63e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—sarcoma	2.02e-06	1.63e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CTNNB1—sarcoma	2.02e-06	1.63e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—SRC—sarcoma	2.02e-06	1.63e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CTNNB1—sarcoma	2.01e-06	1.62e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NRAS—sarcoma	2e-06	1.61e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—SRC—sarcoma	1.97e-06	1.59e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CREB1—sarcoma	1.97e-06	1.59e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—SRC—sarcoma	1.97e-06	1.59e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NRAS—sarcoma	1.94e-06	1.56e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—KRAS—sarcoma	1.94e-06	1.56e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CREB1—sarcoma	1.93e-06	1.56e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—SRC—sarcoma	1.93e-06	1.55e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PLCG1—sarcoma	1.93e-06	1.55e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KIT—sarcoma	1.92e-06	1.55e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—sarcoma	1.92e-06	1.55e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—SRC—sarcoma	1.92e-06	1.55e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—sarcoma	1.91e-06	1.54e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MDM2—sarcoma	1.91e-06	1.54e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—KRAS—sarcoma	1.91e-06	1.54e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—MYC—sarcoma	1.91e-06	1.54e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HRAS—sarcoma	1.91e-06	1.54e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NRAS—sarcoma	1.9e-06	1.53e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—sarcoma	1.89e-06	1.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NRAS—sarcoma	1.89e-06	1.53e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—sarcoma	1.88e-06	1.51e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MDM2—sarcoma	1.87e-06	1.51e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—sarcoma	1.87e-06	1.5e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—MYC—sarcoma	1.86e-06	1.5e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NRAS—sarcoma	1.85e-06	1.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCND1—sarcoma	1.85e-06	1.49e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NRAS—sarcoma	1.84e-06	1.49e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—JUN—sarcoma	1.84e-06	1.49e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—sarcoma	1.83e-06	1.48e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCND1—sarcoma	1.83e-06	1.48e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CREB1—sarcoma	1.83e-06	1.48e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CTNNB1—sarcoma	1.83e-06	1.48e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—JUN—sarcoma	1.83e-06	1.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—SRC—sarcoma	1.83e-06	1.47e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—sarcoma	1.82e-06	1.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SRC—sarcoma	1.82e-06	1.46e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PLCG1—sarcoma	1.81e-06	1.46e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CTNNB1—sarcoma	1.81e-06	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MDM2—sarcoma	1.81e-06	1.46e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—sarcoma	1.81e-06	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KRAS—sarcoma	1.81e-06	1.46e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—MYC—sarcoma	1.81e-06	1.46e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KDR—sarcoma	1.8e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—sarcoma	1.8e-06	1.45e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PLCG1—sarcoma	1.8e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MYC—sarcoma	1.77e-06	1.43e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—sarcoma	1.77e-06	1.42e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—KRAS—sarcoma	1.76e-06	1.42e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—JUN—sarcoma	1.76e-06	1.42e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NRAS—sarcoma	1.76e-06	1.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NRAS—sarcoma	1.75e-06	1.41e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CTNNB1—sarcoma	1.75e-06	1.41e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—sarcoma	1.73e-06	1.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—sarcoma	1.72e-06	1.39e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KRAS—sarcoma	1.72e-06	1.39e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—sarcoma	1.71e-06	1.38e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—sarcoma	1.69e-06	1.36e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—sarcoma	1.68e-06	1.35e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KRAS—sarcoma	1.67e-06	1.35e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCND1—sarcoma	1.67e-06	1.34e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—JUN—sarcoma	1.66e-06	1.34e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KIT—sarcoma	1.66e-06	1.34e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SRC—sarcoma	1.65e-06	1.33e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CTNNB1—sarcoma	1.65e-06	1.33e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—sarcoma	1.65e-06	1.33e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SRC—sarcoma	1.64e-06	1.32e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KRAS—sarcoma	1.63e-06	1.32e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MDM2—sarcoma	1.63e-06	1.32e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KRAS—sarcoma	1.63e-06	1.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—sarcoma	1.63e-06	1.31e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—sarcoma	1.63e-06	1.31e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—sarcoma	1.62e-06	1.31e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—sarcoma	1.62e-06	1.3e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CTNNB1—sarcoma	1.61e-06	1.3e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—sarcoma	1.61e-06	1.3e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—sarcoma	1.6e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MDM2—sarcoma	1.6e-06	1.29e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—sarcoma	1.6e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KRAS—sarcoma	1.59e-06	1.29e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—sarcoma	1.59e-06	1.28e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NRAS—sarcoma	1.59e-06	1.28e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KRAS—sarcoma	1.59e-06	1.28e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CREB1—sarcoma	1.58e-06	1.28e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—SRC—sarcoma	1.58e-06	1.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCND1—sarcoma	1.58e-06	1.27e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NRAS—sarcoma	1.58e-06	1.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—JUN—sarcoma	1.57e-06	1.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—sarcoma	1.56e-06	1.26e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—sarcoma	1.54e-06	1.24e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—sarcoma	1.53e-06	1.23e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NRAS—sarcoma	1.52e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MDM2—sarcoma	1.51e-06	1.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—sarcoma	1.51e-06	1.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—sarcoma	1.5e-06	1.21e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—sarcoma	1.5e-06	1.21e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SRC—sarcoma	1.49e-06	1.2e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—sarcoma	1.48e-06	1.19e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—sarcoma	1.47e-06	1.18e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—sarcoma	1.46e-06	1.18e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—sarcoma	1.46e-06	1.18e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—SRC—sarcoma	1.46e-06	1.18e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—sarcoma	1.45e-06	1.17e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—sarcoma	1.45e-06	1.17e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—sarcoma	1.45e-06	1.17e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—sarcoma	1.44e-06	1.16e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—sarcoma	1.43e-06	1.16e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—sarcoma	1.43e-06	1.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—sarcoma	1.42e-06	1.15e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—sarcoma	1.42e-06	1.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—JUN—sarcoma	1.42e-06	1.14e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SRC—sarcoma	1.41e-06	1.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	1.41e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—sarcoma	1.4e-06	1.13e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO2—sarcoma	1.4e-06	1.13e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—sarcoma	1.39e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HBA1—sarcoma	1.39e-06	1.12e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—sarcoma	1.39e-06	1.12e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JUN—sarcoma	1.39e-06	1.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—sarcoma	1.38e-06	1.12e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—sarcoma	1.38e-06	1.12e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—sarcoma	1.38e-06	1.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—sarcoma	1.37e-06	1.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—sarcoma	1.37e-06	1.1e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—sarcoma	1.36e-06	1.09e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—sarcoma	1.36e-06	1.09e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—sarcoma	1.36e-06	1.09e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—sarcoma	1.35e-06	1.09e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—sarcoma	1.35e-06	1.09e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—sarcoma	1.34e-06	1.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—sarcoma	1.32e-06	1.06e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—sarcoma	1.32e-06	1.06e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—sarcoma	1.31e-06	1.06e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—sarcoma	1.31e-06	1.05e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—sarcoma	1.31e-06	1.05e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—sarcoma	1.31e-06	1.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—sarcoma	1.31e-06	1.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—sarcoma	1.28e-06	1.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—sarcoma	1.28e-06	1.03e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—sarcoma	1.28e-06	1.03e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SRC—sarcoma	1.27e-06	1.03e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—sarcoma	1.26e-06	1.02e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SRC—sarcoma	1.24e-06	1e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	1.24e-06	9.99e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—sarcoma	1.24e-06	9.98e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—sarcoma	1.23e-06	9.96e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—sarcoma	1.22e-06	9.86e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—sarcoma	1.22e-06	9.81e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—sarcoma	1.21e-06	9.78e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—sarcoma	1.21e-06	9.73e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—sarcoma	1.21e-06	9.72e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—sarcoma	1.2e-06	9.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLCG1—sarcoma	1.19e-06	9.57e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SRC—sarcoma	1.18e-06	9.52e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—sarcoma	1.17e-06	9.43e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—sarcoma	1.17e-06	9.42e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—sarcoma	1.16e-06	9.38e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—sarcoma	1.15e-06	9.3e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—sarcoma	1.15e-06	9.27e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—sarcoma	1.14e-06	9.19e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—sarcoma	1.14e-06	9.19e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—sarcoma	1.14e-06	9.17e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—sarcoma	1.14e-06	9.16e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—sarcoma	1.13e-06	9.1e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—sarcoma	1.12e-06	9e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—sarcoma	1.11e-06	8.99e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—sarcoma	1.11e-06	8.96e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—sarcoma	1.1e-06	8.85e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—sarcoma	1.09e-06	8.8e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—sarcoma	1.06e-06	8.53e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—sarcoma	1.05e-06	8.49e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—sarcoma	1.05e-06	8.46e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—sarcoma	1.04e-06	8.38e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—sarcoma	1.03e-06	8.34e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—sarcoma	1.03e-06	8.31e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—sarcoma	1.03e-06	8.27e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SRC—sarcoma	1.02e-06	8.23e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—sarcoma	9.94e-07	8.01e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—sarcoma	9.93e-07	8.01e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—sarcoma	9.82e-07	7.92e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—sarcoma	9.77e-07	7.88e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—sarcoma	9.36e-07	7.55e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—sarcoma	9.16e-07	7.39e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—sarcoma	9.14e-07	7.37e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—sarcoma	8.95e-07	7.22e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—sarcoma	8.94e-07	7.21e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—sarcoma	8.76e-07	7.07e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—sarcoma	8.68e-07	7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—sarcoma	8.45e-07	6.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—sarcoma	8.3e-07	6.7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—sarcoma	7.51e-07	6.06e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—sarcoma	7.18e-07	5.79e-06	CbGpPWpGaD
